HANQUYOU Marks 3rd Anniversary with Brilliant Achievements

(Adnkronos) – SHANGHAI, July 28, 2023 /PRNewswire/ — HANQUYOU (trastuzumab, trade name in Europe: Zercepac®; trade names in Australia: Tuzucip®  and Trastucip®), the first China-developed trastuzumab biosimilar independently developed by Shanghai Henlius Biotech, Inc. (2696.HK), welcomes the 3rd anniversary of its marketing approval in the European Union. HANQUYOU is now indicated for the treatment of HER2-positive early breast cancer, and gastric cancer. It was developed in accordance with the guidelines from the National Medical Products Administration (NMPA), the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). In 27 July and 12 August 2020, HANQUYOU was approved for marketing in European Union and China successively. Up to date, HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions with a global shipment totaling over 3 million units. Moreover, its Biologics License Application (BLA) was accepted by the U.S. FDA, which makes HANQUYOU potentially the first Chinese biosimilar approved in China, the EU, and the U.S. Henlius has aggressively pursued overseas commercialization of HANQUYOU, collaborating with global partners such as Accord, Abbott, Cipla, Eurofarma, Elea, the Jacobson Group, and KG Bio to bring its therapeutics to patients in major biopharmaceutical markets in the U.S., Europe, likewise emerging markets. As of now, HANQUYOU (Zercepac®) has been launched in approximately 20 European countries. Moreover, Henlius further expanded its overseas presence in 2022, with the launch of HANQUYOU in Cambodia, Australia, Singapore, and Argentina. HANQUYOU has been widely used in clinical practice. As of now, HANQUYOU has benefitted about 140,000 patients in China. To benefit more patients, Henlius is continuously enhancing the accessibility of HANQUYOU through efficient market access and expansion. HANQUYOU was included in the National Medical Insurance Catalog of China since it was launched, and it is reimbursed nationally in countries and regions including the United Kingdom (UK), France and Germany. With the rapid market acceptance, HANQUYOU achieved the strong commercial growth. As of the end of 2022, the domestic sales revenue of HANQUYOU reached approximately RMB1.69 billion, and its overseas sales revenue exceeded RMB120 million, while the overseas license revenue was more than RMB280 million. With the vision of "Leaving no HER2-positive patient behind", Henlius will make all-round efforts to enhance the capabilities of innovation, manufacturing, and commercialization, steadily advancing the market expansion of HANQUYOU, and bringing more hopes to patients across the world. 
View original content:https://www.prnewswire.co.uk/news-releases/hanquyou-marks-3rd-anniversary-with-brilliant-achievements-301888159.html
 

 —immediapress/salute-benesserewebinfo@adnkronos.com (Web Info)

Da non perdere
Recensioni
Valutazione di ECCELLENTE
In base a 24 recensioni
Ottima esperienza, Paolo ed Emiliano molto professionali e precisi!
alessandro pasqual
alessandro pasqual
2024-03-26
La conduzione ed i contenuti sono ottimi! Complimenti continuerò a seguirvi!
Angelica Bianco
Angelica Bianco
2024-03-22
Bellissima intervista e giornalisti top
Cristina Orsatti wedding planner
Cristina Orsatti wedding planner
2024-03-22
Casa Radio è una vera innovazione nel settore immobiliare, che permette di ascoltare molteplici temi, legati all’Abitare! Complimenti a tutto il team!
Federico Pagliuca
Federico Pagliuca
2024-03-13
Piacevolissima chiacchierata e notevoli gli spunti ricevuti per una piacevole ed interessante conversazione.
Fernando Caprino
Fernando Caprino
2024-02-21
Professionalità e passione garantita con persone che sanno metterti a tuo agio nel raccontarti e nell’offrire la tua esperienza e riflessioni al loro pubblico. Grazie.
Roberto “Roby'ncool” Vitali
Roberto “Roby'ncool” Vitali
2024-02-19
Ho trovato l’esperienza molto soddisfacente. Grande professionalità ma allo stesso tempo accoglienza.
Cristian Catania
Cristian Catania
2024-02-19
Esperienza interessante ed emozionante, conduttori simpaticissimi e di notevole supporto che mi hanno saputo mettere a mio agio fin da subito.
Stefano Sanciu
Stefano Sanciu
2024-02-19

Collabora con noi

Promuovi il tuo business con noi!

Siamo proiettati al 100% verso il nostro pubblico che, ci segue e si fida per la nostra straordinaria capacitĂ  di scegliere i migliori partners sul mercato.

  • Seleziona categoria

  • Seleziona l'autore